Company: CPMV
Filing Date: 2025-08-19
Form Type: 10-Q
Source: 0001683168-25-006318
Chunk: 26

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-08-19
Form: 10-Q
Item: Part I, Item 1
Chunk 26
---
iv)
a net change in operating assets and liabilities of $330,758 primarily due to an increase in accrued compensation of $327,566.

 20 

Cash Flows From Financing Activities

Net cash provided by financing activities for the
six months ended June 30, 2024 consisted of proceeds received from loan payable from Oncotelic totaling $55,000.

Recently Adopted Accounting Standards

There have been no new accounting pronouncements adopted
by the Company or new accounting pronouncements issued by the Financial Accounting Standards Board during the three and six months ended
June 30, 2025, as compared to the recent accounting pronouncements described in Note 2 of the Company’s Annual Report on Form 10-K
for the year ended December 31, 2024, that the Company believes are of significance or potential significance to the Company.

    Item 3.
    Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company” as defined
in Rule 12b-2 of the Exchange Act, we are not required to provide the information called for by this item.

    Item 4.
    Controls and Procedures

As required by Rule 13a-15(b) under the Exchange
Act, as of June 30, 2025, the end of the period to which this quarterly report relates, we have carried out an evaluation of the effectiveness
of the design and operation of our disclosure controls and procedures. This evaluation was carried out under the supervision and with
the participation of our management, including our President and Chief Executive Officer and Chief Financial Officer.

Disclosure controls and procedures are controls and
other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange
Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s
rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information
required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including the President
and Chief Executive Officer and the EVP, Chief Financial Officer as appropriate, to allow timely decisions regarding required disclosure.
Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance
of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible
controls and procedures.  Based on the evaluation of our disclosure controls and procedures as of June